Kidney Cancer Clinical Trials Consortium

Abstract

Vanderbilt University Medical Center (VUMC) has been an active and engaged participant in the Kidney Cancer Clinical Trials Consortium over the course of the reporting period. VUMChas led the first protocol conducted through the Consortium (Haake, PI) looking at circulating tumor DNA(ctDNA) in advanced renal cell carcinoma (RCC) patients receiving immune-based systemic therapy. Thistrial has accrued X patients out of Y planned and will generate preliminary data for future studies and extramural funding. Further, the first therapeutic study from the Consortium was proposed and will be led by an VUMC investigator (Beckermann, PI) investigating the combination of ipilimumab/nivolumab plus a small molecule inhibitor of the adenosine signaling pathway. Drs. Beckermann and Rini are active participants at the monthly Consortium meetings providing critical feedback regarding new proposals and the general direction and governance of the Consortium.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2022
Accession Number
AD1192611

Entities

People

  • Brian I. Rini

Organizations

  • Vanderbilt University Medical Center

Tags

DTIC Thesaurus Topics

  • Adenosine
  • Biomedical Research
  • Blockades
  • Cells
  • Clinical Trials
  • Consortiums
  • Contracts
  • Covid-19
  • Data Management
  • Department Of Defense
  • Diseases
  • Immune System
  • Instructors
  • Kidney Cancer
  • Kidney Diseases
  • Lymphocytes
  • Maryland
  • Medical Personnel
  • Small Molecules
  • T Lymphocytes
  • Therapy
  • Universities

Fields of Study

  • Medicine

Readers

  • Clinical Trial Research.
  • Defense Technology Research and Development.
  • Oncology